CAJ | 학술논문

目的：探讨利妥昔单抗在血液系统恶性肿瘤疾病中的治疗作用。方法：选择收治的82例血液系统恶性肿瘤患者，按照患者入院先后顺序，将患者进行排列，偶数号作为观察组，奇数号作为对照组，每组41例。观察组患者采用利妥昔单抗治疗，对照组给予吡柔比星注射液，21 d 为1个化疗周期，6个疗程后统计分析两组患者临床有效率及不良反应发生率。结果：观察组与对照组的临床总有效率分别为80.48%（33/41）、60.98%（25/41），两组比较差异有统计学意义（χ2=35.92，P <0.05）；观察组中轻中度骨髓抑制2例（4.88%）、肝功能损害2例（4.88%）、胃肠道不适患者3例（7.32%），对照组中轻中度骨髓抑制5例（12.20%）、肝功能损害8例（19.51%），胃肠道不适患者10例（24.39%），两组比较差异有统计学意义（P <0.05）。结论：利妥昔单抗是一种嵌合人鼠的抗体，与吡柔比星注射液在治疗血液系统恶性肿瘤方面比较，临床上具有更加明显的效果，不良反应相对较少，是安全有效治疗血液系统恶性肿瘤的药物。
목적：탐토리타석단항재혈액계통악성종류질병중적치료작용。방법：선택수치적82례혈액계통악성종류환자，안조환자입원선후순서，장환자진행배렬，우수호작위관찰조，기수호작위대조조，매조41례。관찰조환자채용리타석단항치료，대조조급여필유비성주사액，21 d 위1개화료주기，6개료정후통계분석량조환자림상유효솔급불량반응발생솔。결과：관찰조여대조조적림상총유효솔분별위80.48%（33/41）、60.98%（25/41），량조비교차이유통계학의의（χ2=35.92，P <0.05）；관찰조중경중도골수억제2례（4.88%）、간공능손해2례（4.88%）、위장도불괄환자3례（7.32%），대조조중경중도골수억제5례（12.20%）、간공능손해8례（19.51%），위장도불괄환자10례（24.39%），량조비교차이유통계학의의（P <0.05）。결론：리타석단항시일충감합인서적항체，여필유비성주사액재치료혈액계통악성종류방면비교，림상상구유경가명현적효과，불량반응상대교소，시안전유효치료혈액계통악성종류적약물。
Objective To investigate the role of rituximab in the treatment of hematologic malignancies diseases. Method 82 cases of patients with hematologic malignancies system were chosen. According to the order of patients admitted to hospital,the patients were ar-ranged,the even was as the observation group,and the odd number was as the control group,and 41 cases in each group. The observation group was treated with rituximab therapy,and the control group was taken with injections Pirarubicin. 21 days were as a chemotherapy cy-cle. The clinical effectiveness and toxicity incidence after six treatment groups were taken for statistical analysis. Results The clinical total effective rates of the observation group and the control group were respectively 80. 48%(33 / 41 )and 60. 98%( 25 / 41 ),and the difference was statistically significant(χ2 = 35. 92,P < 0. 05). The mild to moderate bone marrow suppression in the observation group was 2 cases(4. 88% ),2 cases were of liver damage( 4. 88% ),gastrointestinal discomfort was 3 cases( 7. 32% ),the control group with mild to moderate bone marrow suppression was five cases( 12. 20% ),liver dysfunction was 8 cases( 19. 51% ),gastrointestinal discomfort was 10 patients( 24. 39% ),there were significant differences between the two groups(P < 0. 05). Conclusion Rituximab is a chimeric mu-rine antibody,compared with Pirarubicin injection in the treatment of hematologic malignancies,the clinical effect is more significant,and the side effects are relatively few and it is the safe and effective treatment of hematologic malignancies drugs.